Pacific Biosciences of California PACB Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's accrued progress collections and price adjustments?
- Pacific Biosciences of California (PACB) reported accrued progress collections and price adjustments of $3.55M in Q1 2026.
- How has Pacific Biosciences of California's accrued progress collections and price adjustments changed year-over-year?
- Pacific Biosciences of California's accrued progress collections and price adjustments decreased by 39.3% year-over-year, from $5.86M to $3.55M.
- What is the long-term trend for Pacific Biosciences of California's accrued progress collections and price adjustments?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's accrued progress collections and price adjustments has grown at a 20.2% compound annual growth rate (CAGR), from $1.57M to $3.93M.